Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations - detected after initial treatment with chemotherapy - are associated with an increased risk of relapse and poor survival. [More]
MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. [More]
BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences completes acquisition of Cellular Research

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company), today announced it has completed the acquisition of Cellular Research, Inc. [More]
Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Sequenom, UC San Diego Moores Cancer Center collaborate to explore utility of liquid biopsy assay

Sequenom, Inc., a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center. [More]
Mylan releases generic version of Zosyn Injection in the U.S.

Mylan releases generic version of Zosyn Injection in the U.S.

Mylan N.V. today announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's Zosyn Injection. [More]
Holographic tomography company comes to Australia and New Zealand

Holographic tomography company comes to Australia and New Zealand

AXT have been appointed a distributor for Nanolive, an innovative young company specialising in live cell imaging. [More]
MU researchers find that resveratrol affects dogs' immune systems in different ways

MU researchers find that resveratrol affects dogs' immune systems in different ways

Resveratrol, a compound found commonly in grape skins and red wine, has been shown to have several potentially beneficial effects on health, including cardiovascular health, stroke prevention and cancer treatments. However, scientists do not yet fully understand how the chemical works and whether or not it can be used for treatment of diseases in humans and animals. [More]
Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery. [More]
Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer. [More]
Study sheds light on fertility concerns of young breast cancer patients

Study sheds light on fertility concerns of young breast cancer patients

Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back. [More]
BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

Cancer researchers are constantly in search of more-effective and less-toxic approaches to stopping the disease, and have recently launched clinical trials testing a new class of drugs called BET inhibitors. These therapies act on a group of proteins that help regulate the expression of many genes, some of which play a role in cancer. [More]
Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers can help identify, reduce follow-up delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data, developed by researchers at Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer. [More]
Veritas Genetics obtains CE mark approval for myBRCA genetic screening test

Veritas Genetics obtains CE mark approval for myBRCA genetic screening test

Boston-based Veritas Genetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company's hereditary breast and ovarian cancer genetic screening test, myBRCA. Veritas introduced myBRCA, which sequences BRCA1 and BRCA2 genes using proprietary gene-targeting technology and Next Generation Sequencing, in North America in May 2015. [More]
Three medical oncologists to receive ESMO's acclaimed awards

Three medical oncologists to receive ESMO's acclaimed awards

The European Society for Medical Oncology, the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards. [More]
Beta-blockers improve overall survival among epithelial ovarian cancer patients

Beta-blockers improve overall survival among epithelial ovarian cancer patients

In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. [More]
UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas. [More]
MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma. [More]
Low rate of mortality from breast cancer after DCIS diagnosis

Low rate of mortality from breast cancer after DCIS diagnosis

Research published this week estimates that the risk of dying from early stage breast cancer within 20 years of diagnosis is very low (3.3%). [More]
Advertisement
Advertisement